65,437 trials
Asthma
Primary: Rate of Asthma Exacerbations Per Year — 0.69; 0.82 Adjusted annualized exacerbations — p=0.048
COVID-19 · Muscle Atrophy · Muscle Weakness
Primary: Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 363.04; 359.55 miliVolts
Otomycosis
Primary: Therapeutical Cure (Clinical and Mycological Cure) — 48; 10 Participants
Covid-19
Primary: Percentage of Subjects Alive and Free of Respiratory Failure at Day 28 — 40; 38 Participants
Dental Diseases
Primary: Bone Density Assessment — 0.48; 0.46 g/cc
Early Cancer Detection
Primary: Study Data and Samples Were Used for CancerSEEK Assay Development — 712; 3870; 5; 14 Participants
Urinary Stone
Primary: Maximum Pain Intensity Score — 3.6; 3.2 score on a scale — p=0.5
Metastatic Melanoma
Primary: Number of Participants With Treatment-related Grade 3-5 Adverse Events in Arm 1N and Arm 1P — 0; 2; 0; 0 Participants
Percutaneous Coronary Intervention
Primary: Concentration of Pharmacodynamics — 142.5; 210 platelet reaction units
Inflammatory Bowel Diseases · Ulcerative Colitis · Crohn Disease
Primary: Prevalence of Anxiety Episodes (Crohn's Disease) — 262; 892 Participants
Opioid-use Disorder · Pain, Postoperative
Primary: Pain Scores With Movement — 4.57; 4.61; 4.19 score on a scale
Dental Polymer Based Filling Material
Primary: Concentration of Bisphenol A in Saliva — 0.25 ng/ml — p=<0.05
Epistaxis
Primary: Number of Participants With Initial Hemostasis — 10; 11 Participants — p=1.000
Smoking Cessation · Nicotine Addiction · Schizophrenia
Primary: Cigarette Per Day — -3.2; -3.0; -2.71; -2.50 cigarettes per day
Hypertension
Primary: Percent Change From Baseline in Plasma Angiotensinogen (AGT) at Day 57 Compared to Placebo — -3.4; -67.4 percent change — p=< 0.001